|Assessment Status||Rapid review complete|
|Indication||For the treatment of patients aged 3 years and older with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not amenable to surgery|
|Rapid review commissioned||30/09/2011|
|Rapid review completed||14/10/2011|
|Rapid review outcome||Full Pharmacoeconomic Evaluation Recommended|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.